Edition:
United Kingdom

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Capital Market

1.03USD
16 Aug 2018
Change (% chg)

$-0.93 (-47.45%)
Prev Close
$1.96
Open
$1.01
Day's High
$1.04
Day's Low
$0.99
Volume
843,475
Avg. Vol
69,831
52-wk High
$12.80
52-wk Low
$0.99

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)
No analyst recommendations are available for .

Overall

Beta: 2.17
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.98 -- --
ROI: -71.40 1.78 14.61
ROE: -71.40 3.28 16.33

FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

The U.S. Food and Drug Administration declined to approve Pain Therapeutics Inc's abuse-deterrent opioid treatment Remoxy for the fourth time, sending the company's shares down 35 percent to a record low.

06 Aug 2018

UPDATE 2-FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

* Shares fall 35 pct to record low (Adds analyst comment, updates share movement)

06 Aug 2018

U.S. FDA declines to approve Pain Therapeutics' opioid drug

Aug 6 Pain Therapeutics' said on Monday that the U.S. Food and Drug Administration declined to approve the company's opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk.

06 Aug 2018

BRIEF-Pain Therapeutics Q1 Loss Per Share $0.33

* PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER

09 May 2018

BRIEF-Pain Therapeutics Announces FDA Advisory Committee Meeting For Remoxy ER

* PAIN THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY ER®

19 Mar 2018

BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018

* FDA ACCEPTS REMOXY® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018

01 Mar 2018

Competitors

Earnings vs. Estimates